Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 488 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Breaking down changes in NHS cancer waiting times in England August 17, 2023 What to Know About Cancer Clinical Trial Matching Programs March 14, 2023 Beloved Kindergarten Teacher Who Inspired Her Community Dies of Breast Cancer... April 8, 2021 Got the COVID Blues? August 12, 2020 Load more HOT NEWS Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... Multipronged Approach Eliminates Racial Disparities in Early-Stage Lung Cancer Treatment NF1 Associated with More Cancer Types Than Previously Known Five Questions With…Amber.
